Nycomed puts off flotation until US recovers
This article was originally published in Clinica
Executive Summary
Nycomed Amersham, which announced plans to float 10% of its life sciences business last year (see Clinica No 921, p 11), has chosen to put that plan on hold until market conditions in the US become more friendly to companies wishing to raise public capital.